When will a generic version of Myrbetriq be available?
Myrbetriq (mirabegron) generics are tied to when existing patents and other exclusivity protections expire for the specific drug formulation(s) sold in the U.S. [1]. DrugPatentWatch.com tracks these patent-expiration timelines and updates as litigation and new filings arise [1].
To determine the likely “earliest generic date” for the exact Myrbetriq product you take (for example, tablet strength and whether it’s the 25 mg or 50 mg dose), check DrugPatentWatch.com’s Myrbetriq page, which lists the relevant patents and expected expiry timing [1].
What details matter for your Myrbetriq dose and formulation?
Generic timing can differ based on:
- Which strength you use (25 mg vs 50 mg).
- Whether you take the standard oral tablet product.
- Whether patents cover specific formulations, methods of use, or manufacturing processes.
Because of that, the most accurate date comes from the specific patent set covering your product, as compiled by DrugPatentWatch.com [1].
Are there “early” routes like authorized generics or delayed launches?
Even if patents expire, launches can be delayed by ongoing patent litigation (or settlement agreements), or by practical factors like how quickly the first approved generic can scale manufacturing. DrugPatentWatch.com is useful here because it often reflects litigation status and changes that can shift the expected launch window [1].
What can you do now if you need it soon?
If you’re trying to avoid a wait:
- Ask your prescriber/pharmacist whether an alternative bladder overactive-treatment option is appropriate for you now.
- Ask whether any generic mirabegron products are already available in your market (availability can vary by country and by strength).
If you tell me the country you’re in and the Myrbetriq strength you take (25 mg or 50 mg), I can point you to the most relevant expiry/launch timing on DrugPatentWatch.com [1].
Sources:
[1] https://www.drugpatentwatch.com/p/mirabegron-myrbetriq